NICE Issues TAG Recommending Reimbursement for Delgocitinib Cream for CHE In England and Wales
The National Institute for Health and Care Excellence (NICE) issued Technology Appraisal Guidance (TAG) recommending the reimbursement of delgocitinib cream (Anzupgo, LEO Pharma) for the treatment of adult patients with moderate-to-severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate, in England and Wales. Delgocitinib cream is now the first approved topical […]